A post by @FirstSquawk on X.

Eli Lilly reported that its drug Foundayo significantly reduced the apnea-hypopnea index and improved weight and cardiovascular risk factors at 52 weeks. The announcement, distributed via First Squawk, marks a key clinical milestone for the therapy in obstructive sleep apnea. The results matter because they support Foundayo's potential across both sleep apnea severity and cardiometabolic health, broadening its case beyond a single indication. Investors will watch for full trial data, regulatory next steps, and how the profile compares with rival sleep apnea and weight-loss treatments.